Lupin Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is TRAVOPROST USP, with a corresponding US DMF Number 26878.
Remarkably, this DMF maintains an Active status since its submission on April 19, 2013, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of October 24, 2014, and payment made on February 12, 2014, indicating their dedication to facilitating drug approvals, Categorized as Type II